Evidence map›Paper›PMID 36203196›Full record

ArticleJournal of medical case reports2022

Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report.

Chee Keong Chang, Alvin Oliver Payus, Malehah Mohd Noh, Meryl Grace Lansing, Doreen Sumpat, Sooth Jiun Andrea Lu, Boon Teong Yew

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Signal mining and risk analysis of olanzapine adverse events in the FAERS database.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chee Keong ChangMedicine-Based Department, Faculty of Medicine and Health Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia. changdoc_1@yahoo.com.
Alvin Oliver PayusMedicine-Based Department, Faculty of Medicine and Health Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.
Malehah Mohd NohMedicine-Based Department, Faculty of Medicine and Health Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.
Meryl Grace LansingMedicine-Based Department, Faculty of Medicine and Health Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.
Doreen SumpatMedicine-Based Department, Faculty of Medicine and Health Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.
Sooth Jiun Andrea LuDepartment of Medicine, Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia.
Boon Teong YewDepartment of Medicine, Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia.
Universiti of Malaysia Sabah · MYQueen Elizabeth Hospital · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe present this case to draw attention to the importance of early diagnosis in terms of life-saving, noting that greater awareness is important among healthcare professionals. Our patient developed neuroleptic malignant syndrome (NMS) after his neuroleptic drug dosage was increased. His condition was complicated by acute kidney injury (AKI) which required hemodialysis. The uniqueness of this case is that the causative agent of NMS is an atypical antipsychotic, and atypical antipsychotics are generally considered to be safer than typical antipsychotics. CASE PRESENTATION: A 31-year-old Chinese man with underlying schizophrenia presented to our hospital with aggressive behavior. He was admitted to the psychiatric hospital and started on his regular medications, with an increase in the dose of olanzapine tablet from 5 to 10 mg daily. After 5 days in the ward, the patient was noted to have high fever, restlessness, confusion, increased muscle rigidity, tachycardia and tachypnoea. Antipsychotic therapy was stopped in view of suspected NMS. The first laboratory test for serum creatine kinase (CK) showed a markedly high level of this molecule. His renal profile showed raised serum creatinine in comparison to 2 months prior when the baseline serum creatinine was within the normal range. A diagnosis of NMS with AKI was made. Although the patient was given adequate intravenous fluid hydration with close monitoring of urine output, his renal function did not show improvement but continued to show a worsening trend. In view of this, he was started on urgent hemodialysis. The patient was dependent on intermittent hemodialysis before his AKI showed complete recovery. After 2 weeks, his blood test results returned to normal. He was discharged well.

conclusionNeuroleptic malignant syndrome is a life-threatening iatrogenic medical emergency in which high index of clinical suspicion is required for diagnosis and prompt treatment.

Indexed as

Acute Kidney InjuryAntipsychotic AgentsNeuroleptic Malignant SyndromeAdultCreatine KinaseCreatinineHumansMaleOlanzapineRenal DialysisTabletsAntipsychotic AgentsCreatine KinaseCreatinineOlanzapineTabletsAcute kidney injuryCreatine kinaseNeuroleptic malignant syndrome

Identifiers

PMID36203196
PMCPMC9535839
OpenAlexW4302293149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.